Cadwalader allows sharing content.
Email to a friend or colleague:
From
To
Subject
Email Cadwalader is advising AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for oncology, vascular access, and peripheral vascular disease, on its definitive agreement to sell its NAMIC® fluid management portfolio to Medline Industries, Inc. for $167.5 million. The transaction is subject to customary closing conditions, including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. https://www.cadwalader.com/news/news-release/cadwalader-advises-angiodynamics-on-sale-of-namic-fluid-management-business-to-medline-industries-for-1675-million